Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study checks if Triple-Inhaler trimbow really helps COPD patients Day-to-Day

NCT ID NCT06480890

Disease control Sponsor: Chiesi Farmaceutici S.p.A. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at how well the Trimbow inhaler works for people with COPD when used in everyday life, not just in a lab. 362 adults with COPD used the inhaler for 12 weeks. Researchers measured changes in a COPD symptom questionnaire to see if patients felt better. The goal was to see if this triple-combination inhaler improves breathing and quality of life outside of strict clinical trial conditions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Trimbow (beclometasone, formoterol, glycopyrronium) inhaler
What this could lead to
If successful, this study could confirm that Trimbow helps COPD patients breathe better and manage their condition more effectively in everyday life.
What could go wrong
This is a small, short-term study without a comparison group, so results may not prove the drug works better than other treatments. It also only looks at symptom scores, not long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

362 people

The number who actually took part.

Started

Jul 2024

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Subjects with COPD (≥40 years and CAT total score ≥10) in China, who have newly initiated BDP/FF/GB without previous use of single inhaler triple therapy, and without recent hospitalisation for a COPD exacerbation. Detailed inclusion and exclusion criteria are listed below. Any treatment decision must have been taken prior to and independently of the subject's inclusion in the study.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects who are willing and able to give their written consent to participate in the study 2. Aged ≥40 years at BDP/FF/GB initiation 3. Had documented diagnosis of COPD prior to BDP/FF/GB initiation 4. Baseline CAT total score ≥10 (at the time of BDP/FF/GB initiation OR within the 12 weeks prior to treatment initiation, if no CAT total score is available on BDP/FF/GB initiation date) 5. Subjects who have initiated treatment with BDP/FF/GB within 12 weeks prior to informed consent form (ICF) signature, or on date of ICF signature Exclusion Criteria: 1. Subjects who had been admitted to hospital for a COPD exacerbation within the last 4 weeks prior to BDP/FF/GB initiation 2. Subjects who are not likely to come back 12-weeks after BDP/FF/GB initiation, per Investigator judgement 3. Participation in any clinical trial in the 4 weeks prior to BDP/FF/GB initiation 4. Subjects had used any other single inhaler triple therapy before or at BDP/FF/GB initiation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • Site 156101 - The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510120, China

  • Site 156102 - Mianyang Central Hospital

    Mianyang, Sichuan, 450003, China

  • Site 156103 - Shaoxing People's Hospital

    Shaoxing, Zhejiang, 312000, China

  • Site 156105 - Taizhou Central Hospital

    Taizhou, Zhejiang, 318000, China

  • Site 156106 - Huzhou Central Hospital

    Huzhou, Zhejiang, 313000, China

  • Site 156108 - Henan Provincial People's Hospital

    Zhengzhou, Henan, 450003, China

  • Site 156109 - Shandong Provincial Hospital

    Jinan, Shandong, 250021, China

  • Site 156110 Beijing Jingmei Group Genetal Hospital

    Beijing, Beijing Municipality, 102300, China

  • Site 156112 - The First Affiliated Hospital of Ningbo University

    Ningbo, Zhejiang, 315010, China

  • Site 156113 - The Second Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, 510260, China

  • Site 156114 - The Second Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, 524003, China

  • Site 156115 - Jinhua Central Hospital

    Jinhua, Zhejiang, 321083, China

  • Site 156117 - The Second Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, 710004, China

  • Site 156119 - Peking University People's Hospital

    Beijing, Beijing Municipality, 100033, China

  • Site 156121 - The First Affiliated Hospital of Xinjiang Medical University

    Ürümqi, Xinjiang Uygur, 830054, China

  • Site 156122 - Deyang People's Hospital

    Deyang, Sichuan, 618000, China

  • Site 156123 - Wenling People's Hospital

    Wenling, Zhejiang, 317599, China

  • Site 156124 - Lishui People's Hospital

    Lishui, Zhejiang, 323088, China

  • Site 156125 - Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, 210008, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.